Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

JCARE Announcement on Obtaining Drug Registration Certificate for Pixavir Marboxil Capsules

Time:2025-12-11

Ad hoc announcement pursuant to Art53 LR JCARE Announcement on Inclusion of the Products in the National Reimbursement Drug List

Time:2025-12-08

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2025 Second Extraordinary General Meeting

Time:2025-11-14

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2025 Second Extraordinary General Meeting

Time:2025-10-24

Ad hoc announcement pursuant to Art. 53 LR -JCARE 2025 Third Quarterly Report

Time:2025-10-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE 2025 Interim Report

Time:2025-08-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization for Drugs

Time:2025-08-15

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Achievement of The Primary Endpoint In Phase III Clinical Trials of Recombinant Anti-Human Il-17aF Humanized Monoclonal Antibody Injection

Time:2025-07-21

Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2024 Profit Distribution of JCARE

Time:2025-07-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-06-24

< 1234...15 >